With 2.74 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.57 million shares. During the session, the Medical Devices company that operates in wider Healthcare sector, reached to the highest price of $0.8394 whereas the lowest price it dropped to was $0.7. The 52-week range on ICCM shows that it touched its highest point at $1.57 and its lowest point at $0.48 during that stretch. It currently has a 1-year price target of $3.22.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ICCM was up-trending over the past week, with a rise of 37.15%, but this was up by 27.87% over a month. Three-month performance surged to 10.81% while six-month performance fell -34.45%. The stock lost -4.26% in the past year, while it has lost -27.10% so far this year. A look at the trailing 12-month EPS for ICCM yields -0.29 with Next year EPS estimates of -0.24. For the next quarter, that number is -0.07. This implies an EPS growth rate of 13.54% for this year and 12.05% for next year.
Float and Shares Shorts:
At present, 45.73 million ICCM shares are outstanding with a float of 24.12 million shares on hand for trading. On 2024-10-15, short shares totaled 0.29 million, which was 52.0 higher than short shares on 1726185600. In addition to Mr. Eyal Shamir as the firm’s CEO & Director, Mr. Ronen Tsimerman CPA serves as its CFO & COO.
Institutional Ownership:
Through their ownership of 0.00735 of ICCM’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-06-30, ICCM reported revenue of $1011000.0 and operating income of -$3228000.0. The EBITDA in the recently reported quarter was -$3146000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ICCM since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
